calcifidiol

Calcifidiol (25-hydroxyvitamin D3) is a naturally occurring metabolite of vitamin D3 produced in the liver. It serves as the primary clinical indicator of vitamin D status and is further hydroxylated in the kidneys to calcitriol, the active hormonal form. In the context of oncology, calcifidiol is investigated for its ability to bind the vitamin D receptor (VDR), which regulates genes involved in cell proliferation, differentiation, and apoptosis. The US Department of Veterans Affairs conducted a Phase 2 clinical trial (NCT00018538) to evaluate calcifidiol's potential to induce cell differentiation and inhibit angiogenesis in men with subclinical biochemical relapses of prostate cancer (rising PSA levels) following definitive therapy. The study aimed to determine if vitamin D metabolite therapy could delay or prevent disease progression in patients with low tumor burdens.

Other names

calcifidol25-hydroxyvitamin D325-hydroxycholecalciferol